In this review:
Monitor for HBV reactivation with DAA agents
Glecaprevir/pibrentasvir in HCV GT 1–6 with renal disease
Sofosbuvir/velpatasvir/voxilaprevir for 8 weeks in HCV GT3
MK-3682/grazoprevir/ruzasvir ± ribavirin HCV GT1–3
“de novo” HCC in DAA-treated HCV
Explaining ledipasvir/sofosbuvir HCV treatment failure
Statins: survival advantage in alcoholic cirrhosis
Meal timing: a modifiable risk factor for NAFLD?
Cenicriviroc improves fibrosis in NASH
Nivolumab promising in unresectable HCC
Reduced changes in BMD with TDF vs TAF in HBV
No benefit from modest alcohol use in NAFLD
Please login below to download this issue (PDF)